Skip to content

← 18 Aug 2026 · All rebalances

Short-term Top 10 — Health Care — 24 Aug 2026

The ten as they stood on 24 Aug 2026. Scores, pillars and reasons are the ones recorded that day; nothing here is recomputed. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100.

The short-term score is a published weighted sum of percentile ranks, rebalanced every Monday. A list is a published formula and its output, not a recommendation. Method version 3.

Get this list's changes by email

Who entered, who left, and the reason — with the score moves behind it.

Sign in to subscribe Subscriptions are available to signed-in accounts while email delivery is being set up.

Informational only — not financial advice. The daily email has not started yet — subscribing now puts you on the list for the first one. Unsubscribe in one click.

The ten

#CompanyWhy it was hereSectorScore
1 Merck & Co. (MRK)
Volume and participation 94th: trading volume is about normal versus its 30-day average.

Volume and participation 94th: trading volume is about normal versus its 30-day average; catalysts 90th: the analyst consensus rating has improved toward "buy" since the prior reading; weakest is setup 38th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months).

  • Trend86.7
  • Momentum53.7
  • Setup37.6
  • Volume and participation94.3
  • Catalysts90.0
Health Care 72.1
2 HINGE HEALTH INC CLASS A (HNGE)
Volume and participation 97th: it gapped 14.9% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed.

Volume and participation 97th: it gapped 14.9% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; catalysts 78th: open-market insider buys in 90 days 42, analysts have raised their average price target by 1.3% since the prior reading; weakest is setup 46th: no Elliott-wave labelling currently fits its swings. Its short interest was not measured, so no short-interest deduction applies.

  • Trend74.5
  • Momentum69.2
  • Setup45.6
  • Volume and participation96.5
  • Catalysts77.9
Health Care 71.6
3 ZENAS BIOPHARMA INC (ZBIO)
Setup 92nd: no fresh 20-day breakout up or down.

Setup 92nd: no fresh 20-day breakout up or down; catalysts 77th: analysts have raised their average price target by 8.0% since the prior reading; weakest is momentum 50th: MACD momentum is negative. It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies.

  • Trend73.9
  • Momentum49.9
  • Setup92.3
  • Volume and participation59.4
  • Catalysts77.3
Health Care 71.3
4 GLAUKOS CORP (GKOS)
Trend 87th: a strong uptrend, with buyers in control.

Trend 87th: a strong uptrend, with buyers in control; catalysts 77th: open-market insider buys in 90 days 27, analysts have raised their average price target by 1.8% since the prior reading; weakest is setup 48th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 3% of it.

  • Trend86.9
  • Momentum63.1
  • Setup48.3
  • Volume and participation72.0
  • Catalysts77.1
Health Care 70.2
5 IMMUNOME INC (IMNM)
Catalysts 91st: open-market insider buys in 90 days 30, the analyst consensus rating has improved toward "buy" since the prior reading.

Catalysts 91st: open-market insider buys in 90 days 30, the analyst consensus rating has improved toward "buy" since the prior reading; trend 83rd: a strong uptrend, with buyers in control; weakest is setup 46th: day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months). It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies.

  • Trend82.5
  • Momentum71.7
  • Setup45.8
  • Volume and participation47.9
  • Catalysts91.3
Health Care 69.6
6 DEFINIUM THERAPEUTICS INC (DFTX)
Catalysts 90th: analysts have raised their average price target by 12.2% since the prior reading.

Catalysts 90th: analysts have raised their average price target by 12.2% since the prior reading; volume and participation 77th: it gapped 16.1% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is momentum 53rd: MACD momentum is negative.

  • Trend68.2
  • Momentum53.4
  • Setup60.5
  • Volume and participation77.2
  • Catalysts90.2
Health Care 69.5
7 Revolution Medicines (RVMD)
Trend 81st: a strong uptrend, with buyers in control.

Trend 81st: a strong uptrend, with buyers in control; catalysts 73rd: open-market insider buys in 90 days 25, analysts have raised their average price target by 0.6% since the prior reading; weakest is setup 47th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 2% of it.

  • Trend81.0
  • Momentum71.4
  • Setup46.9
  • Volume and participation64.7
  • Catalysts73.1
Health Care 68.2
8 KINIKSA PHARMACEUTICALS INTERNATIO (KNSA)
Trend 88th: a "golden cross" — its 50-day average is above its 200-day.

Trend 88th: a "golden cross" — its 50-day average is above its 200-day; catalysts 61st: open-market insider buys in 90 days 31, the analyst consensus rating is unchanged since the prior reading; weakest is setup 58th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 3% of it. Its short interest was not measured, so no short-interest deduction applies.

  • Trend88.0
  • Momentum58.0
  • Setup57.6
  • Volume and participation60.3
  • Catalysts61.4
Health Care 66.4
9 Moderna (MRNA)
Catalysts 96th: analysts have raised their average price target by 75.7% since the prior reading.

Catalysts 96th: analysts have raised their average price target by 75.7% since the prior reading; trend 80th: it is trading 100.2% above its 50-day average, the short-term trend line; weakest is setup 49th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). Its score is docked 5 points for short interest in the heaviest tenth of the field.

  • Trend79.8
  • Momentum72.6
  • Setup48.9
  • Volume and participation50.5
  • Catalysts96.0
Health Care 66.0
10 NUVATION BIO INC CLASS A (NUVB)
Trend 71st: it is trading 14.0% above its 50-day average, the short-term trend line.

Trend 71st: it is trading 14.0% above its 50-day average, the short-term trend line; setup 70th: no Elliott-wave labelling currently fits its swings; weakest is catalysts 58th: the analyst consensus rating has softened toward "sell" since the prior reading. It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies.

  • Trend70.7
  • Momentum69.1
  • Setup70.3
  • Volume and participation58.9
  • Catalysts58.0
Health Care 66.0

Entered on 24 Aug 2026

Merck & Co. (MRK) — Entered 24 Aug 2026: score 72.1, rank 1 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).

ZENAS BIOPHARMA INC (ZBIO) — Entered 24 Aug 2026: score 71.3, rank 3 (vs 18 Aug 2026).

GLAUKOS CORP (GKOS) — Entered 24 Aug 2026: score 70.2, rank 4 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).

Revolution Medicines (RVMD) — Entered 24 Aug 2026: score 68.2, rank 7 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).

KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) — Entered 24 Aug 2026: score 66.4, rank 8 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).

Moderna (MRNA) — Entered 24 Aug 2026: score 66.0, rank 9 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).

NUVATION BIO INC CLASS A (NUVB) — Entered 24 Aug 2026: score 66.0, rank 10 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).

Left on 24 Aug 2026

Agilent Technologies (A) — Left 24 Aug 2026: score 62.5, rank 30 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).

BridgeBio Pharma, Inc. (BBIO) — Left 24 Aug 2026: score 52.9, rank 105 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).

CELLDEX THERAPEUTICS INC (CLDX) — Left 24 Aug 2026: score 55.5, rank 86 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).

Encompass Health (EHC) — Left 24 Aug 2026: score 58.5, rank 49 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).

EDGEWISE THERAPEUTICS INC (EWTX) — Left 24 Aug 2026: score 64.3, rank 17 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).

MINIMED INC (MMED) — Left 24 Aug 2026: score 61.3, rank 38 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).

Veeva Systems (VEEV) — Left 24 Aug 2026: score 62.7, rank 28 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).

See every rebalance of this list →

Informational only — NOT financial advice.

Research stocks in your own words.

Informational only — NOT financial advice.

ScreenersBlogPrivacyiOS app